A Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age
Latest Information Update: 27 Jun 2024
At a glance
- Drugs Fremanezumab (Primary)
- Indications Headache; Migraine
- Focus Adverse reactions
- Acronyms SPACE
- Sponsors Teva Branded Pharmaceutical Products R&D
- 22 Feb 2024 Planned End Date changed from 28 Jul 2027 to 21 Mar 2026.
- 22 Feb 2024 Planned primary completion date changed from 10 Mar 2027 to 1 Nov 2025.
- 18 Aug 2023 Planned End Date changed from 7 Nov 2027 to 28 Jul 2027.